Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 6,274 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Steroid Clear all

Conditions: Fragile X-associated Tremor/Ataxia Syndrome
Interventions: Allopregnanolone; Drug
Lead sponsor: Randi J. Hagerman, MD; Other
Eligibility: 50 Years to 85 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Graft-versus-host Disease
Interventions: Itacitinib, Placebo, Methylprednisolone, Prednisone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 39
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more

Conditions: Prostate Cancer, Thromboembolism
Interventions: docetaxel, doxorubicin hydrochloride, estramustine phosphate sodium, ketoconazole, warfarin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
Interventions: Cholestyramine, Leflunomide, Steroid Therapy; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
Interventions: Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo; Drug · Device
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 7,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 11
States / cities: Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Early Stage HER2+ Breast Cancer
Interventions: Neratinib, Loperamide, Colestipol, Budesonide; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Corona, California • Fullerton, California + 36 more

Conditions: Multiple Myeloma
Interventions: Daratumumab, Pomalidomide, All-trans retinoic acid, Dexamethasone; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Lymphoma
Interventions: Bleomycin sulfate, Stanford V regimen, Doxorubicin hydrochloride, Etoposide, Mechlorethamine hydrochloride, Prednisone, Vinblastine, Vincristine sulfate; Biological · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Advanced Solid Tumors
Interventions: SNV4818, Fulvestrant, Palbociclib; Drug
Lead sponsor: Pikavation Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide Induction, Sequential Maintenance Therapy; Drug
Lead sponsor: Cristina Gasparetto; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer, Gynecologic Cancer
Interventions: prasterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 280
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 185 more

Conditions: Cardiovascular Disease
Interventions: Cholecalciferol, Placebo; Dietary Supplement
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Omaha, Nebraska

Conditions: Carbon Monoxide Poisoning, Carbon Monoxide Intoxication, Carbon Monoxide Encephalopathy, Carbon Monoxide-induced Parkinsonism
Interventions: saline placebo, Dexamethasone; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Overweight
Interventions: LY3437943, Ethinyl Estradiol, Drospirenone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: South Miami, Florida • San Antonio, Texas

Conditions: Cholelithiasis
Interventions: Extracorporeal Shock Wave Lithotripsy, ursodiol; Device · Drug
Lead sponsor: Medstone International; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 2
States / cities: Houston, Texas • Richmond, Virginia

Conditions: Metastatic Castration-resistant Prostatic Neoplasms
Interventions: Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401; Biological · Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 43 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 134
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Coronary Heart Disease
Interventions: Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy Volunteers
Interventions: Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC); Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Chronic Kidney Disease, Kidney Transplantation
Interventions: Doxercalciferol, placebo, 25-OH Vitamin D3; Drug
Lead sponsor: Mariana Markell; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
Interventions: Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone; Drug
Lead sponsor: James A. Tumlin, MD; Other
Eligibility: 75 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Lawrenceville, Georgia • Bethlehem, Pennsylvania

Conditions: Lysosomal Diseases, Gangliosidosis, GM1
Interventions: AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam; Biological · Procedure · Drug + 3 more
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 12 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Respiratory Failure
Interventions: Cuff Leak Test, Dexamethasone 4mg; Diagnostic Test · Drug
Lead sponsor: St. Joseph's Healthcare Hamilton; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

SNV4818 in Participants With Advanced Solid Tumors

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Role of Vitamin D in Secondary Prevention of Cardiovascular Events

Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Lithotripsy for the Treatment of Gallstones

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

Relationship Between the Menstrual Cycle and Heart Disease in Women

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients

Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients